ORAGENICS INCOGENEarnings & Financial Report
Oragenics Inc is a US-based biopharmaceutical company specializing in oral health solutions. It develops and commercializes consumer oral care probiotics, prescription therapeutics for oral mucositis and dental infections, serving healthcare providers and consumer markets primarily across North America.
Revenue
$30.4K
Gross Profit
N/A
Operating Profit
$-3.6M
Net Profit
$-3.6M
Gross Margin
N/A
Operating Margin
-11860.3%
Net Margin
-11811.2%
YoY Growth
N/A
EPS
$-1.85
ORAGENICS INC Q2 FY2022 Financial Summary
ORAGENICS INC reported revenue of $30.4K for Q2 FY2022, with a net profit of $-3.6M (up 5.9% YoY) (-11811.2% margin).
Key Financial Metrics
| Total Revenue | $30.4K |
|---|---|
| Net Profit | $-3.6M |
| Gross Margin | N/A |
| Operating Margin | -11860.3% |
| Report Period | Q2 FY2022 |
ORAGENICS INC Annual Revenue by Year
ORAGENICS INC annual revenue history includes year-by-year totals (for example, 2023 revenue was $37.7K).
| Year | Annual Revenue |
|---|---|
| 2023 | $37.7K |
| 2022 | $131.5K |
ORAGENICS INC Quarterly Revenue & Net Profit History
ORAGENICS INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2023 | $0 | — | $-12.7M | N/A |
| Q3 FY2023 | $7.5K | -91.3% | $-2.0M | -26960.7% |
| Q2 FY2023 | $13.2K | -56.7% | $-3.1M | -23175.5% |
| Q1 FY2023 | $17.0K | +12.9% | $-2.8M | -16710.7% |
| Q4 FY2022 | $0 | — | $-2.2M | N/A |
| Q3 FY2022 | $86.0K | — | $-3.9M | -4497.7% |
| Q2 FY2022 | $30.4K | — | $-3.6M | -11811.2% |
| Q1 FY2022 | $15.1K | — | $-4.6M | -30438.2% |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15083 | $30391 | $86047 | $0 | $17024 | $13163 | $7466 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | 12.9% | -56.7% | -91.3% | N/A |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $23.6M | $20.4M | $17.1M | $14.8M | $12.1M | $8.5M | $7.9M | $5.0M |
| Liabilities | $1.7M | $1.7M | $1.8M | $1.7M | $1.9M | $1.2M | $1.4M | $1.8M |
| Equity | $22.0M | $18.7M | $15.3M | $13.0M | $10.2M | $7.3M | $6.5M | $3.2M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.6M | $-3.4M | $-3.8M | $-2.4M | $-2.1M | $-2.6M | $-1.5M | $-1.1M |